# A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

> **NCT03852498** · PHASE3 · COMPLETED · sponsor: **Genetix Biotherapeutics Inc.** · enrollment: 35 (actual)

## Conditions studied

- Cerebral Adrenoleukodystrophy (CALD)

## Interventions

- **GENETIC:** Lenti-D

## Key facts

- **NCT ID:** NCT03852498
- **Lead sponsor:** Genetix Biotherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-24
- **Primary completion:** 2023-07-24
- **Final completion:** 2023-07-24
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03852498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03852498, "A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03852498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*